For K, the one big take away is the patient now in 15 cycles and currently at 350 mg/m2. This indicates to me that there is therapeutic benefit at that level and it will most definitely be one of the Phase 2 arms and likely to be a multiple dose per week.
2nd, the patient who left the trial can no longer be described as "cherry picked" nor regarded as an outlier as there are now two reported showing a high response to K along side a total of 21 (I think this number might be higher, but it is in my notes) who had increased p21 expression.
Then there was his statement that the highest dose at 750 was declared the MTD which was the subject of great debate a few weeks back.
For the moment, having audio only, there seemed to be data on the slides not elaborated in the presentation. I want to look at that once posted before I say anything more.
News 
Market Data 
Discover 
